CLL

clinical topic updates

by Jennifer R. Brown, MD, PhD

Advances in the understanding of the pathobiology of chronic lymphocytic leukemia (CLL) have led to the success of targeted therapies such as Bruto......READ MORE

clinical topic updates

by Susan O’Brien, MD

The BCL-2 inhibitor venetoclax has an established role in the treatment of chronic lymphocytic leukemia (CLL), but its utilization in the community......READ MORE

clinical topic updates

by John C. Byrd, MD

Second-generation Bruton tyrosine kinase (BTK) inhibitors differ from ibrutinib in their off-target activity. Some of these differences might allow......READ MORE

clinical topic updates

by John C. Byrd, MD

In chronic lymphocytic leukemia (CLL), Bruton tyrosine kinase (BTK) inhibition disrupts key mechanisms that allow malignant B cells to survive. In ......READ MORE

clinical topic updates

by Ian W. Flinn, MD, PhD

Noncovalent, reversible Bruton tyrosine kinase (BTK) inhibitors hold promise for patients with previously treated chronic lymphocytic leukemia (CLL......READ MORE